These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 26721244

  • 1. The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
    Blumenthal DT, Mendel L, Bokstein F.
    J Neurooncol; 2016 May; 127(3):493-502. PubMed ID: 26721244
    [Abstract] [Full Text] [Related]

  • 2. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
    Field KM, Simes J, Nowak AK, Cher L, Wheeler H, Hovey EJ, Brown CS, Barnes EH, Sawkins K, Livingstone A, Freilich R, Phal PM, Fitt G, CABARET/COGNO investigators, Rosenthal MA.
    Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
    [Abstract] [Full Text] [Related]

  • 3. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Heiland DH, Masalha W, Franco P, Machein MR, Weyerbrock A.
    J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
    Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS.
    J Neurooncol; 2012 Mar; 107(1):155-64. PubMed ID: 21986722
    [Abstract] [Full Text] [Related]

  • 5. Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study).
    Rivoirard R, Chargari C, Guy JB, Nuti C, Peoc'h M, Forest F, Falk AT, Garin C, Adjabi A, Hoarau D, Fotso MJ, Langrand Escure J, Moriceau G, Fournel P, Boutet C, Magné N.
    Chemotherapy; 2016 Mar; 61(5):269-74. PubMed ID: 27057742
    [Abstract] [Full Text] [Related]

  • 6. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U.
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS.
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [Abstract] [Full Text] [Related]

  • 8. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
    Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE.
    J Clin Oncol; 2010 Jun 20; 28(18):3069-75. PubMed ID: 20479404
    [Abstract] [Full Text] [Related]

  • 9. Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
    Tabouret E, Barrie M, Thiebaut A, Matta M, Boucard C, Autran D, Loundou A, Chinot O.
    J Neurooncol; 2013 Sep 20; 114(2):191-8. PubMed ID: 23756726
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
    Sepúlveda JM, Belda-Iniesta C, Gil-Gil M, Pérez-Segura P, Berrocal A, Reynés G, Gallego O, Capellades J, Ordoñez JM, La Orden B, Balañá C.
    Clin Transl Oncol; 2015 Sep 20; 17(9):743-50. PubMed ID: 26033428
    [Abstract] [Full Text] [Related]

  • 11. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
    Zhang G, Huang S, Wang Z.
    J Clin Neurosci; 2012 Dec 20; 19(12):1636-40. PubMed ID: 23047061
    [Abstract] [Full Text] [Related]

  • 12. Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
    Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U.
    Acta Oncol; 2016 Dec 20; 55(4):418-22. PubMed ID: 26828563
    [Abstract] [Full Text] [Related]

  • 13. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
    Brandes AA, Finocchiaro G, Zagonel V, Reni M, Caserta C, Fabi A, Clavarezza M, Maiello E, Eoli M, Lombardi G, Monteforte M, Proietti E, Agati R, Eusebi V, Franceschi E.
    Neuro Oncol; 2016 Sep 20; 18(9):1304-12. PubMed ID: 26951379
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
    Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Fouladi M, Kun LE.
    Neuro Oncol; 2014 Jan 20; 16(2):310-7. PubMed ID: 24311632
    [Abstract] [Full Text] [Related]

  • 15. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.
    Gururangan S, Fangusaro J, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Gajjar A, Goldman S, Friedman HS, Packer RJ, Boyett JM, Kun LE, McLendon R.
    Neuro Oncol; 2012 Nov 20; 14(11):1404-12. PubMed ID: 23019233
    [Abstract] [Full Text] [Related]

  • 16. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
    Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF.
    Neuro Oncol; 2017 Jan 20; 19(1):89-98. PubMed ID: 27580889
    [Abstract] [Full Text] [Related]

  • 17. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
    Kaloshi G, Diamandi P, Cakani B, Brace G, Rroji A, Petrela M.
    Tumori; 2015 Jan 20; 101(1):41-5. PubMed ID: 25702676
    [Abstract] [Full Text] [Related]

  • 18. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
    Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS.
    J Clin Oncol; 2007 Oct 20; 25(30):4722-9. PubMed ID: 17947719
    [Abstract] [Full Text] [Related]

  • 19. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
    Rahman R, Hempfling K, Norden AD, Reardon DA, Nayak L, Rinne ML, Beroukhim R, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Alexander BM, Huang RY, Wen PY, Lee EQ.
    Neuro Oncol; 2014 Nov 20; 16(11):1523-9. PubMed ID: 24958095
    [Abstract] [Full Text] [Related]

  • 20. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
    Schaub C, Greschus S, Seifert M, Waha A, Blasius E, Rasch K, Landwehr C, Mack F, Schäfer N, Stuplich M, Kebir S, Vilz B, Scheffler B, Boström J, Simon M, Urbach H, Glas M, Herrlinger U.
    Oncology; 2013 Nov 20; 85(3):191-5. PubMed ID: 24008924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.